Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi CEO Upbeat Despite Medivation M&A Miss, Sarilumab Diss

Executive Summary

During third-quarter earnings report, Brandicourt said he remains confident about Sanofi's prospects in oncology despite losing the takeover fight for Medivation, although he didn't rule out another mid-sized bolt-on attempt if the opportunity arose.

Advertisement

Related Content

Sarilumab Set To Clear EU Hurdle In RA But Actemra Specter Remains
Baricitinib Complete Response May Put Lilly/Incyte Behind IL-6 Blockers In RA
Pressed Sanofi CEO Hopes For Positive Dupixent Launch, Praluent Ruling
4Q Pharma Results Preview, Part 3: Gilead, GSK, Sanofi, Allergan, Shire, Bayer, Valeant
Will Sanofi Overpay For Actelion Innovation Or, Like J&J, Also Walk Away?
Novo Nordisk Shakes Up R&D Strategy To Cope With US Pricing Pressures
Pfizer’s $14bn Medivation Buyout Shows How Far Pharma Will Go In Oncology
Bold Brandicourt Plots Mega Sanofi And Boehringer Animal, Consumer Asset Swap
Brandicourt's 'Big Reveal' Falls Flat For Sanofi
Lantus Loss Drags Down Sanofi's Diabetes Franchise

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097568

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel